Introduction
A number of genetic alterations are involved in oncogenesis, including inactivation of the tumor suppressor genes p53, p16, and retinoblastoma (Rb), and ampli®cation of epidermal growth factor (EGF) receptor gene. One alteration that occurs frequently in a variety of human tumors is loss of heterozygosity at chromosome 10q23. A tumor suppressor gene at 10q23.3, designated MMAC/PTEN (Steck et al., 1997; encoding a dual-speci®city phosphatase with lipid (Maehama and Dixon, 1998) and protein phosphatase activity (Meyers et al., 1997) , has been shown to play an important role in the pathogenesis of a variety of human cancers including, glioblastoma , melanoma, prostate, breast, and endometrial cancers (Guldberg et al., 1997; Cairns et al., 1997; Rhei et al., 1997; Tashiro et al., 1997; Liaw et al., 1997; Marsh et al., 1997) . Germline MMAC/PTEN mutations are present in patients with Cowden disease and Bannayan-Zonana syndrome Marsh et al., 1997) suggesting that inactivation of MMAC/PTEN plays important roles in tumorigenicity. In addition, the phenotype of MMAC/ PTEN null mice supports the conclusion that MMAC/ PTEN functions as a tumor suppressor (Stambolic et al., 1998; Di Cristofano et al., 1998) .
A key step in understanding the role of MMAC/ PTEN as a tumor suppressor is to determine its anti tumor eects in glioma cells. The expression of MMAC/ PTEN in cells de®cient in the wild-type gene product has revealed that MMAC/PTEN is involved in the modulation of a number of cellular processes including growth, survival, cell morphology, and metabolism. The introduction of wild-type MMAC/PTEN into a number of dierent cancer cells has been shown to inhibit their growth and or survival (Furnari et al., 1997; Davies et al., 1998; Li and Sun, 1998) . In addition, the sequence similarity of MMAC/PTEN to tensin (Steck et al., 1997; lead Tamura et al. (1998) to conclude that MMAC/PTEN regulates cell interactions with the extracellular matrix (ECM) by inhibiting cell migration, spreading, and focal adhesions.
There is evidence that many cells are dependent on adhesion to the ECM for their continued survival and that degradation of the ECM by the array of proteolytic enzymes expressed by in®ltrating tumor cells is a common feature of invasion (Mignatti and Rifkin et al., 1993; Moscatelli and Rifkin, 1988) . Matrix metalloproteinases (MMPs), a family of zincdependent neutral endopeptidases, which are capable of degrading almost all ECM components, have been suggested to play an important role in mediating tumor invasion (Vassalli and Pepper, 1994; Cockett et al., 1994; Sato et al., 1994) . The increased expression of various MMPs by many peripheral tumors is strongly associated with the invasive phenotype. MMPs are the principal secreted proteinases, and their activity is controlled at the levels of gene transcription, zymogen activation by proteolysis, and inhibition of active forms by tissue inhibitors of metalloproteinases (TIMPs) (Edwards et al., 1996) .
A hallmark of invasive tumors is their ability to degrade the surrounding ECM, resulting in a compromised matrix organization and disruption of tissue boundaries. Glioblastoma multiforme is a highly malignant central nervous system tumor that is extremely refractory to therapy, in part because of aggressive tendency of the tumor cells to invade (Uhm et al., 1997; Yong et al., 1998) . Numerous in vitro and in vivo studies have documented a direct correlation between high levels of MMP expression and increased invasive capacity of a large number of glioma cell lines (Stetler-Stevenson et al., 1996; Himelstein et al., 1995; BarilleÂ et al., 1997; Sato et al., 1992) . MMP expression has also been documented in both human gliomas and stromal cell lines. (Apodaca et al., 1990; Nakano et al., 1995; Rao et al., 1994; Uhm et al., 1996) .
Although substantial progress has been made in characterizing the invasive behavior of malignant gliomas in vitro and in vivo (Bjerkvig et al., 1986) , the factors responsible for invasiveness are poorly understood. Because the ability to invade seems to be correlated with the degree of malignancy and because MMAC/PTEN activity is lost during progression, we investigated the ability of MMAC/PTEN to modulate MMP-2 expression in human glioma cell lines. Our results indicated that restoration of MMAC/PTEN expression in glioma cells increased apoptosis after detachment from the ECM and reduced the invasive phenotype, which correlated well with the decreased MMP-2 expression and MMP-2 promoter activity.
Results
Our eorts have primarily been directed towards investigating the roles that MMAC/PTEN plays in cancer biology. A major focus of our study is to further understand how MMAC/PTEN is involved in cancer progression. MMAC/PTEN is frequently mutated or deleted in a wide variety of human cancers (Steck et al., 1997; Li et al., 1997) particularly in gliomas. We have examined various cell lines for MMAC/PTEN expression to identify those cells that might be suitable for studying the role of MMAC/ PTEN in tumor cell progression. Among them, the U251 glioma cell line possessed a 273 ins TT mutation and U87 contain a splice site mutation that results in an in-frame deletion of MMAC/PTEN exon 3, thus lacked MMAC/PTEN expression (Steck et al., 1997) . Stable cell lines were generated by infecting the human glioblastoma cell lines U251 and U87 with a retroviral vector expressing wild-type MMAC/PTEN, a control retroviral vector or a vector containing a phosphataseinactive mutant form of MMAC/PTEN (C124S). Drug-resistant (G418) transfectants were identi®ed and harvested for analysis. Immunoblotting analysis showed similar levels of MMAC/PTEN protein expression in representative clones of cells transfected with both wild-type and mutant MMAC/PTEN, whereas no MMAC/PTEN expression was detected in the parental and vector control cell lines (Figure 1 ). U251 cells acutely infected with an adenovirus expressing wild-type MMAC/PTEN (Davies et al., 1998) had a high level of MMAC/PTEN expression and were used as a positive control.
Effect of MMAC/PTEN on cell growth and morphology
We next examined the eect of MMAC/PTEN expression on cellular morphology. The parental U251 cells had a refractile morphology (Figure 2a ) and piled up. Expression of MMAC/PTEN in these cells changed the transformed morphology to a morē attened con®guration ( Figure 2A ). Cells expressing empty vector or the phosphatase-inactive (C124S) form of MMAC/PTEN had transformed morphologies similar to those of the parental U251 cells. Therefore, expression of MMAC/PTEN reversed the transformed phenotype of U251 glioma cells, and the phosphatase domain appeared to be essential for this reversion.
To test whether MMAC/PTEN suppresses growth in vitro, a cell growth assay was performed. Expression of MMAC/PTEN in U251 cells produced inhibition of cell Figure 2B ) similar to that reported previously (Cheney et al., 1999; Davies et al., 1998) . Cell growth was not inhibited by the C124S MMAC/PTEN, indicating the importance of the phosphatase domain in MMAC/PTEN's growth suppression.
Restoration of MMAC/PTEN expression in U251 glioma cells induces anoikis
Many mammalian cell types are dependent on adhesion to the ECM for their continued survival. When signals from matrix are interrupted, normal cells may undergo apoptosis in a process called anoikis (Frisch and Francis, 1994) . In contrast, the ability of malignant cells to proliferate without adhesion, called anchorage-independent growth, correlates closely with tumorigenicity. Davies et al. (1998) reported that adenovirus mediated MMAC/PTEN expression in U251 cells increases the rate of apoptosis after detachment from ECM. We also investigated whether stable restoration of MMAC/PTEN can induce anoikis in these cells. As shown in Figure 3 , MMAC/PTEN sensitized glioma cells to apoptotic stimuli and U251 cells expressing MMAC/PTEN underwent anoikis at a signi®cantly higher rate than the control cell lines. At 48 h, U251 cells and cells containing vector control and the phosphatase-inactive form of MMAC/PTEN were alive and had formed large spheroids in suspension ( Figure 3) . Most of the MMAC/PTEN-expressing cells were dead then and we could not observe signi®cant sizable spheroids ( Figure 3 ). These results suggested that MMAC/PTEN may play a pivotal role in glioma cell metastasis and progression.
Restoration of MMAC/PTEN expression in glioma cells inhibits invasion
To determine whether MMAC/PTEN inhibited the invasive capablity of glioma cells, an important hallmark of malignant gliomas, we used a matrigel in vitro invasion assay (Mohanam et al., 1993) . Fewer MMAC/PTEN-expressing cells invaded through the membrane, and comparable numbers of parental and the vector control cells invaded through membrane ( Figure 4A ,C). Furthermore, cells expressing the inactive form of MMAC/PTEN had an invasive ability similar to that of the control cells ( Figure 4A ,C). Quantitative analysis of the number of cells showed that only 32% of the MMAC treated cells invaded to the lower side of the membrane in comparison to the 100% for both the parental U251 and vector control cells ( Figure 4B ). Additionally, 80% of the phosphatase inactive form of Figure  4D ). These results demonstrated that MMAC/PTEN may exert its tumor-suppressive eect by partly inhibiting tumor invasion and that the phosphatase activity of the MMAC/PTEN is essential for this function.
Correlation of MMAC/PTEN's inhibition of invasion with MMP-2 activity
The expression of several MMPs involved in tumor invasion, including MMP-2 has been shown to be elevated in human gliomas (Apodaca et al., 1990) . We investigated whether MMAC/PTEN in¯uenced the relationship between MMP-2 activity and tumor cell invasion. A gelatin zymography assay (Nakajima et al., 1993) was used to assess the enzymatic activity of MMP-2 in the conditioned medium (CM) from each cell line. As shown in Figure 5D , CM from U251 and U87 cells transfected with vector alone revealed a clear lytic zone at the molecular weight of 72 kDa demonstrating the secreted enzymatic activity of MMP-2. In contrast, the intensity of the lytic zone was greatly reduced in the CM from MMAC/PTENexpressing cells indicating the inhibitory eect of MMAC/PTEN on MMP-2 activity. Furthermore, Figure 4 MMAC/PTEN inhibition of cell invasion in glioma cells. Transfected and parental U251 (A and B) and U87 (C and D) cells that invaded through matrigel-coated trans well inserts were stained with hema-3 stain. Quantitaion of the percentage of U251 (C) and U87 (D) cells that invaded after 48 h was determined by counting under a microscope in ®ve pre-determined ®elds at a magni®cation of 6200. An average of ®ve individual experiments is shown expression of C124S-MMAC/PTEN mutant (data not shown) in U251 cells exhibited similar enzymatic activity of MMP-2 to that of the parental control suggesting that MMAC/PTEN must be functional to alter MMP-2 activity. These results strongly demonstrate that restoration of functional MMAC/PTEN in U251 and U87 cells inhibits MMP-2 enzymatic activity and consequently diminishes the invasion ability of tumor cells. The eects of MMAC/PTEN on MMP-2 were speci®c, as reintroduction of MMAC/PTEN did not alter phorbol-12-myristate-13-acetate (PMA) stimulated MMP-9 expression ( Figure 5B ).
Effect of MMAC/PTEN on MMP-2 and TIMP-2 mRNA expression
We also investigated whether the eect of MMAC/ PTEN on the enzymatic activity of MMP-2 was a consequence of reduced mRNA expression by using an RNase protection assay (RPA). As MMP-2 and TIMP-2 cooperate to regulate the ECM degradation, we analysed both MMP-2 and TIMP-2 mRNA levels in these cell lines. As shown in Figure 6A and B, U251 and U87 cells expressing control vector expressed detectable levels of MMP-2 mRNA that correlated with its enzymatic activity ( Figure 5A ). The C124S mutant-expressing cells, however, expressed slightly more MMP-2 mRNA ( Figure 6C,D) . More importantly, cells expressing MMAC/PTEN express much less MMP-2 mRNA. These results suggested that MMAC/PTEN inhibits biosynthesis of MMP-2 and consequently reduces enzymatic activity. There was an excellent correlation between MMP-2 expression and invasion activity. In addition, we also analysed expression of TIMP-2, which has an important role in MMP-2 regulation. Cells expressing MMAC/PTEN expressed slightly more TIMP-2 than did vector control cells; there was an inverse correlation between MMP-2 and TIMP-2 expression.
MMAC/PTEN inhibits transcription of MMP-2 gene
To investigate whether MMAC/PTEN inhibits MMP-2 expression at the transcriptional level, we examined its eects on the activity of an MMP-2 promoterluciferase construct. High, similar levels (15-fold more than that of promoterless luciferase construct) of luciferase activity were noted in the parental and vector control cells ( Figure 7A ) and correlated well with zymography ( Figure 5 ) and RPA results ( Figure  6 ). However, the activity of the MMP-2/luciferase reporter gene was inhibited in MMAC/PTEN-expressing cells to ®vefold more than that of the promoterless luciferase control, a 80% reduction ( Figure 7A ). Furthermore, luciferase activity in C124S MMAC/ PTEN expressing cells was higher than that of its wildtype counterpart reiterating the importance of functional MMAC/PTEN in regulating MMP-2 expression. A transient transfection assay was performed with increasing amounts of MMAC/PTEN expression plasmid or control plasmid (5, 10, 25, 50, 100, 200, 400 and 800 ng, 1, 2 and 4 mg) to transfect U251 glioma cells and a ®xed amount of MMP-2 luciferase reporter construct. U251 cells transfected with control plasmid served as a control. A 13 ± 15-fold induction of MMP-2 luciferase activity was observed in U251 cells transfected with control plasmid. We observed that in this system, as low as 100 ng of MMAC/PTEN was sucient enough to inhibit MMP-2 gene expression (fourfold maximum induction). Taken together, these results strongly support a role for the MMAC/PTEN to transcriptionally regulate MMP-2 gene expression.
Discussion
Our data demonstrated that expression of MMAC/ PTEN signi®cantly inhibited invasion of glioma cells and reduced MMP-2 expression and activity. Consistent with its role as a tumor suppressor gene involved in tumor progression, MMAC/PTEN also induced anoikis in transformed cells, suggesting that loss of MMAC/PTEN may increase the metastatic potential of tumor cells by increasing the survival of cells involved in invasion.
It is important to elucidate the cellular functions of MMAC/PTEN to determine how MMAC/PTEN (Davies et al., 1998) con®rming the tumor suppressor role of MMAC/ PTEN. The results of our work and of two previous studies Tian et al., 1999) indicated that overexpression of an exogenous wildtype MMAC/PTEN in glioma cells that do not express endogenous MMAC/PTEN modi®es the transformed phenotype of the cancer cells and that catalytic activity is required for this eect. Furthermore, stable expression of MMAC/PTEN in U251 glioma cells inhibited growth and induced anoikis, which is supported by the observation that knockout of MMAC/PTEN locus resulted in the cells with an increased anchorage-independent growth (Di Cristofano et al., 1998). We also showed that the catalytically inactive form (C124S) of MMAC/PTEN increased the growth and survival of U251 glioma cells under anchorage-independent conditions. Our results are consistent with those of previously reported studies (Furnari et al., 1998; Cheney et al., 1999) in which growth inhibition of glioma cells was also observed after restoration of MMAC/PTEN expression.
Many mammalian cell types are dependent on adhesion to ECM for survival and undergo apoptosis when signals from the matrix are interrupted. In this study, restoration of MMAC/PTEN induced anoikis. In support of this, Lu et al. (1999) have reported that expression of MMAC/PTEN in human breast cells also induces apoptosis after substrate detachment. Because reduced sensitivity to anoikis appears to be a hallmark of oncogenesis and of metastasis, it will be important to further characterize how MMAC/PTEN is involved in cancer progression, as loss of MMAC/PTEN increases the metastatic potential of tumor cells by increasing the survival of cells involved in invasion. We have shown that MMAC/PTEN markedly inhibited cell invasion more than 70% in U251 cells. Since catalytically inactive mutant C124SMMAC/PTEN did not inhibit cell invasion which suggests that the phosphatse domain is necessary for invasion. Two dierent groups have recently shown that MMAC/ PTEN inhibits cell invasion. Maier et al. (1999) showed that while MMAC/PTEN can inhibit cell invasion in U87 and LN229 glioma cells, the inhibition is independent of the MMAC/PTEN status of the cell and of the catalytic core domain of MMAC/PTEN. On the other hand Tamura et al. (1999) showed that overexpression of MMAC/PTEN in U87 cells reduces invasion in a phosphatase-dependent manner. There- Figure 6 Eect on cellular levels of MMP-2 and TIMP-2 mRNA. Total RNA was isolated from U251 (A) and U87 (B) cells and was analysed by RPA for MMP-2, TIMP-2 and GAPDH mRNA expression fore, the anti cancer eect of MMAC/PTEN may be modulated at least by two independent factors: MMAC/PTEN-mediated growth suppression and inhibition of invasiveness.
A common feature of the invasive process is the degradation of the surrounding ECM by an array of proteolytic enzymes expressed by the in®ltrating tumor cells (Mignatti and Rifkin, 1993; Moscatelli and Rifkin, 1988) . Matrix metalloproteinases, capable of degrading almost all ECM components, have been suggested to play an important role in mediating tumor invasion (Vassalli and Pepper, 1994; Cockett et al., 1994; Sato et al., 1994) . In this regard the elevated expression of various MMPs by many peripheral tumors is strongly associated with the invasive phenotype (Mignatti and Rifkin, 1993; Vassalli and Pepper, 1994; Sato et al., 1994; Rucklidge et al., 1994; Moser et al., 1994; Seftor et al., 1993; Agarwal et al., 1994; Albini et al., 1991; Davies et al., 1993) . Several studies have implicated the expression of MMP-2 with invasion in vitro and in vivo (Albelda, 1993; Mignatti and Rifkin, 1993; . Several oncogenes can induce the expression of MMP-2 and can be suppressed by dierent pharmacological agents and growth factors (Mignatti and Rifkin, 1993) . Several groups have shown that reintroduction of MMP-2 cDNA increases the invasive phenotype and that antisense MMP-2 cDNA would antagonize the invasive phenotype seen by MMP-2 reintroduction (Deryugina et al., 1997; Fang et al., 2000; Xuan et al., 1998) . We also showed that MMAC/ PTEN reduced MMP-2 expression and activity in U251 and U87 glioma cells. MMAC/PTEN inhibition of MMP-2 was observed at several levels involving lytic activity of gelatin as determined by zymography, on MMP-2 mRNA expression and on MMP-2 promoter activity. Therefore, the exogenous MMAC/PTEN reduced invasion and proteolytic activity of MMAC/ PTEN defective U251 glioma cells, dramatically impairing their ability to invade in vitro. These observations raise the interesting possibility of exploring the precise intracellular signaling mechanism of control of MMP-2 expression by the tumor suppressor gene MMAC/PTEN. In addition, the logical step would be to explore the presence of various regulatory elements in the MMP-2 promoter that might be directly or indirectly controlled by MMAC/PTEN tumor suppressor. The MMP-2 promoter has a number of potential cis-acting regulatory elements (Qin et al., 1998) but we do not know if MMAC/PTEN exerts its inhibitory response through any of these elements. However, NF-kB-dependent activation of MMP-2 has been documented (Kim and Koh, 2000) . We recently showed that MMAC/PTEN expression blocks the activation of NF-kB (Koul et al., 2001) , thus raising the possibility that MMAC/PTEN regulates MMP-2 expression by an NF-kB-dependent pathway. Studies are under way to map MMAC/PTEN inhibitory elements in the human MMP-2 promoter. Because invasive growth is a biological hallmark of malignant gliomas that still counteracts most therapeutic approaches, the use of protease inhibitors or tumor suppressor genes as anti-invasion agents may be an eective adjunct to the hitherto limited therapeutic options. 
Materials and methods

Cells
U251 and U87 human glioblastoma cell lines (ATCC) were maintained in culture medium (DMEM/F12, 5% fetal bovine serum) in a humidi®ed atmosphere containing 5% CO 2 at 378C. U251 and U87 cells were shown previously to have mutated MMAC/PTEN gene (U251 has 723 ins TT and U87 has a splice site mutation that results in an in-frame deletion of exon 3) and do not express a detectable protein product (Steck et al., 1997) .
Retroviral gene construction and stable transfections
pLNCX, a 6.2-kb retroviral vector (Clontech) derived from Moloney murine leukemia virus, (MoMuLv), was used for retroviral gene delivery and expression. A full-length wildtype MMAC/PTEN retroviral construct was generated by ligating the NotI-SalI fragment from pBluescript-MMAC/ PTEN into the NotI-SalI sites in the multiple cloning site of pLNCX. Mutation in the phosphatase domain (C124S) was generated in pBluescript-MMAC/PTEN by using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) and mutant MMAC/PTEN gene was then inserted into pLNCX. Sequences were con®rmed with the USB reagent kit (Amersham Life Sciences) for DNA sequencing with Sequenase T 7 DNA polymerase and 7-deaza-dGTP. Retrovirus producer cells PT67 were grown in DMEM/F12 containing 10% fetal calf serum, 1000 U/ml penicillinstreptomycin, and 2 mM glutamine, and transfected with wild-type and mutant construct of MMAC/PTEN by calcium phosphate precipitation. The human glioblastoma cell lines U251 and U87 were infected with 48-h supernatants from the transfected PT67 cells. After 14 h of incubation, the cells were maintained in DMEM/F12 plus 5% fetal calf serum and colonies were selected by using 400 mg/ml G418. Drugresistant colonies were expanded to generate clonal cell lines. Twenty colonies were picked, expanded, and screened for the expression of MMAC/PTEN protein by immunoblotting. Ten clones were screened for various assays to avoid clonal variability. The data presented here are representative of four dierent clones expressing MMAC/PTEN.
Immunoblotting
For cytoplasmic cell lysates, the cells were washed with icecold phosphate buered saline and lysed by incubation on ice in a buer containing 50 mM HEPES pH 7.0, 150 mM NaCl, 1 mM EGTA, 100 mM NaF, 10 mM Na 4 P 2 O 7 , 10% glycerol, 1% Triton X-100, 1 mM Na 3 VO 4 , 1 mM pepstatin, 10 mg/ml aprotinin, 5 mM iodoacetic acid, and 2 mg/ml leupeptin. The lysates were clari®ed by centrifugation, and proteins in the supernatant were resolved by 7.5% SDS ± PAGE, electroblotted to PVDF membranes (Millipore), blocked in 5% skim milk in 16TBS, 0.05% Tween-20, and probed with primary antibodies. Anti-MMAC/PTEN monoclonal antibody was from Santa Cruz (Santa Cruz, CA, USA). Proteins were detected with an enhanced chemiluminescence kit (ECL, Amersham, Chicago, IL, USA) following incubation with horseradish peroxidase-conjugated goat anti-mouse antibody.
Cell growth assay
U251 cells were seeded in triplicate in DMEM/F12 supplemented with 5% fetal bovine serum at 1610 4 cells per well in 6-well plates and counted on the indicated days with a hemocytometer.
Anoikis
U251 cells were trypsinized, and the number of viable cells was determined by trypan blue exclusion (it was always 495%). Equal numbers of viable cells were plated on petri dishes in culture medium and placed on a rocker in a humidi®ed atmosphere. After 0, 24 and 48 h, the cells were collected, subjected to a brief trypsin treatment to dissociate spheroids, counted, ®xed in 1% paraformaldehyde and stored in 70% ethanol at 48C. The cells were processed and analysed for apoptosis with an Apo-BrdU kit (Phoenix Flow Systems, Inc., San Diego, CA, USA).
Cell invasion assay
Invasion of glioma cells in vitro was measured by the invasion of the cells through Matrigel-coated transwell inserts (Mohanam et al., 1993) . Brie¯y, transwell inserts with 8 mm pore were coated with 0.78 mg/ml matrigel in cold serum-free medium. The cells were trypsinized and 100 ml of cell suspension (1610 6 cells/ml) was added in triplicate wells. After 48 h of incubation, the cells that passed through the ®lter into the lower wells were stained with hema-3 stain kit (Biochemical Science Inc) and the cells in ®ve pre-determined ®elds were counted with a microscope and expressed as 100% set for U251/U87 or vector control cells that invaded to the lower side of the chamber.
Gelatin substrate gel zymography
Zymography was performed by a minor modi®cation of the procedure described by Nakajima et al. (1993) by using 7.5% (w/v) sodium dodecyl sulfate-polyacrylamide gels impregnated with 0.1% (w/v) gelatin. Cells were plated at 1610 6 cells/100-mm dish in DMEM containing 5% fetal bovine serum until they were 80% con¯uent. Then they were washed and fed with fresh serum-free medium. To measure MMP-9 expression, the cells were treated with or without phorbol-12-myristate-13-acetate (PMA) for 6 ± 8 h, and then the culture medium was replaced with fresh serum free medium. Supernatants as CM were collected after 48 h, and equal amounts of protein were mixed with SDS sample buer without reducing agent and subjected to SDS ± PAGE. After electrophoresis, the gels were washed several times in 2.5% Triton X-100 for 1 h at room temperature to remove the SDS and then incubated for 24 ± 48 h at 378C in buer containing 5 mM CaCl 2 and 1 mM ZnCl 2 . The gels were stained with (0.25%) Coomassie blue for 30 min and then destained for 1 h in a solution of acetic acid and methanol. Proteolytic activity was visualized as clear bands (zones of gelatin degradation) against the blue background of stained gelatin.
RNA isolation and RNase protection assay (RPA)
Total RNA was isolated from monolayers of U251 and U87 glioma cell lines incubated under the conditions described above. RPA was performed with a Riboquant RNase Protection assay kit (Pharmingen, San Diego, CA, USA) as per the manufacturer's protocol. Brie¯y, 10 mg of total RNA was hybridized with MMP-2 or TIMP-2 (5610 4 c.p.m.) and GAPDH (2.5610 4 c.p.m.) riboprobes (Qin et al., 1998) . The mixture was heated at 908C initially, the temperature was allowed to decrease to 568C in a 4800 PCR machine (PerkinElmer), and the samples were incubated overnight. The hybridized mixture was then treated with RNase A/T1, and the protected fragments were analysed by 5% denaturing (8 M urea) PAGE. The protected fragments of MMP-2, TIMP-2, and GAPDH are 324, 530, and 230 bp, respectively.
Reporter assays
A luciferase reporter plasmid driven by 1716 bp of the human MMP-2 promoter (Bian and Sun, 1997) was used in this study, and the reporter vector pTK b (Clontech, Palo Alto, CA, USA) expressing b-galactosidase under the control of the herpes simplex virus thymidine promoter was used as an internal reference plasmid. U251, U251 vector control, U251 MMAC/PTEN and U251 MMAC/PTEN C124S cells were plated in 6-well tissue culture plates and transfected the following day with 2 mg of the MMP-2 reporter construct and 1 mg of the pTKb construct by using the FuGene TM reagent (Roche Molecular Biochemicals) according to manufacturer's protocol. After 24 h, the cells were lysed and assayed with an enhanced luciferase assay kit (PharMingen). Extracts were assayed in triplicate for luciferase and bgalactosidase enzyme activity. The luciferase activity of each sample was normalized to b-galactosidase activity before the fold activation value relative to U251 and vector control cells was calculated.
For transient transfection assay U251 cells were plated in six well tissue culture plates and transfected the following day. One set of cells was transfected with increasing amounts (5 ng ± 4 mg) of MMAC/PTEN expression plasmid, and 1 mg of the MMP-2 reporter construct and 1 mg of the pTKb construct with the FuGene TM reagent according to manufacturer's protocol. Another set of U251 cells was transfected with increasing amounts (5 ng ± 4 mg) of a control plasmid together with 1 mg of the MMP-2 reporter construct and 1 mg of the pTKb construct. After 24 h, luciferase activity was assessed as described above.
Abbreviations MMAC/PTEN, mutated in multiple advanced cancers/ phosphatase and tensin homologue; ECM, extracellular matrix; MMP, matrix metalloproteinases; TIMPs, tissue inhibitors of metalloproteinases; CM, conditioned medium; DMEM, Dulbecco's modi®ed Eagle's medium.
